Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroblastoma 2Neoplasm Metastasis 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oropharyngeal Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

lenvatinib 16Bevacizumab 14sintilimab 10tislelizumab 9apatinib 9regorafenib 6camrelizumab 6donafenib 5atezolizumab 5Immune Checkpoint Inhibitors 4Hepatectomy 4cabozantinib 3Radiosurgery 3Capecitabine 3spartalizumab 2pembrolizumab 2durvalumab 2anlotinib 2Surgical Procedures, Operative 2Specimen Handling 2Oxaliplatin 2Observation 2Magnetic Resonance Spectroscopy 2Injections 2Immunotherapy 2Folfox protocol 2Fecal Microbiota Transplantation 2Electroporation 2Blood Specimen Collection 2ursodoxicoltaurine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Hepatocellular × fludarabine phosphate × Clear all
NCT06641453 2024-10-16

CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma

Chinese PLA General Hospital

Phase 1/2 Not yet recruiting
30 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡